Sandramycin 

Sandramycin ia a cyclic depsipeptide antibiotic isolated from cultured broth of a Nocardioides sp. Sandramycin is also a DNA intercalator that potently binds DNA and is an ADC cytotoxin. Sandramycin is active against Gram-positive bacteria and has potent antitumor activity^[1][2][3].

Sandramycin has antimicrobial activity wtih MIC values of 0.024 μg/mL, 0.012 μg/mL, 0.012 μg/mL, 0.098 μg/mL, 0.024 μg/mL, 12.5 μg/mL and 12.5 μg/mL for Bacillus subtilis (Rec⁺) A22508-2, B. subtilis (Rec^-) A22509-2-2, Staphylocccus aureus 209P-A9497, S. aureus (echinomycin-resistant) A9628, Streptococcus faecalis A96 1 1, Escherichia coli A151 19 and E. coli (actinomycin-sensitive) A21780 (AS-19), respectively^[1].
Sandramycin inhibits cancer cells growth of L1210, B16, HCT118, RPMI8226, A431, RKO, SU-DHL6 and SU-DHL10 cells with IC₅₀ values of 0.02 nM, 0.07 nM, 0.8 nM, 3.8 nM, 3.1 nM, 1.3 nM, 5.9 nM and 3.3 nM, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sandramycin (0.0125-1.6 mg/kg; intraperitoneal injection; daily; for 5 days; CDF1 female mice) treatment shows moderately active in vivo against leukemia P388 in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1221.32

C₆₀H₇₆N₁₂O₁₆

100940-65-6

CC(C)[C@@H](C(OC[C@@H](NC(C1=C(O)C=C(C=CC=C2)C2=N1)=O)C3=O)=O)N(C)C(CN(C)C(CNC([C@@H]4CCCCN4C([C@@H](COC([C@H](C(C)C)N(C)C(CN(C)C(CNC([C@H]5N3CCCC5)=O)=O)=O)=O)NC(C6=C(O)C=C(C=CC=C7)C7=N6)=O)=O)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. J A Matson, et al. Sandramycin, a Novel Antitumor Antibiotic Produced by a Nocardioides Sp. Production, Isolation, Characterization and Biological Properties. J Antibiot (Tokyo). 1989 Dec;42(12):1763-7.  [Content Brief]

  [2]. Katsushi Katayama, et al. Total Synthesis of Sandramycin and Its Analogues via a Multicomponent Assemblage. Org Lett. 2014 Jan 17;16(2):428-31.  [Content Brief]

  [3]. D L Boger, et al. DNA Binding Properties of Key Sandramycin Analogues: Systematic Examination of the Intercalation Chromophore. Bioorg Med Chem. 1999 Feb;7(2):315-21.  [Content Brief]